Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 11Recruiting 7Completed 2Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Diseases 1Neoplasms by Site 1Neoplasms 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Biliary Tract Carcinoma 1

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 14Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5capivasertib 4Epirubicin 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Fulvestrant 3Blood Specimen Collection 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × camrelizumab × Clear all
NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Harbin Medical University

Phase 2 Active not recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡